drugset / Trial / NCT00349245

Dexmedetomidine vs. Remifentanil for Sedation During AFI

NCT00349245

RandomizedParallel-groupDouble-blind

Summary

The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared to Remifentanil. The hypothesis is that Dexmedetomidine will provide at least equal if not better conditions (sedation and analgesia) required for awake fiberoptic intubation (Ramsay Sedation Scale 3) with less respiratory and cardiovascular adverse effects, as well as less recall than Remifentanil.

Timeline

Start
2006-06
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified
Subject Remifentanil Small molecule

Indications

No indication recorded.